文献速递临床免疫质量管理与危急值

甲状腺球蛋白自身抗体检测在甲状腺癌随访中的分析与临床性能比较

Analytical and clinical performance of thyroglobulin autoantibody assays in thyroid cancer follow-up.
PubMed 文献 · Clin Chem Lab Med · 2017-01-01

该研究比较了四种常用甲状腺球蛋白自身抗体(TgAb)免疫分析在甲状腺癌随访中的分析与临床性能,用质谱法测Tg和四对Tg/TgAb免疫分析检测576份样本。结果显示TgAb免疫分析间定量与定性一致性中等,部分试剂用定量下限(LOQ)可提高干扰性TgAb检出,所有试剂作为疾病替代标志物临床性能欠佳,Tg与TgAb联合可 modestly 改善。

要点

  • 四种TgAb免疫分析间定量与定性一致性仅中等(R² 0.20-0.70,κ 0.41-0.66/0.47-0.71)。
  • Beckman、Siemens、Thermo用LOQ与URI检出干扰性TgAb率相似,Roche用URI时明显较低。
  • TgAb阳性者TgAb免疫分析ROC AUC 0.59-0.62,与Tg相近,联合Tg与TgAb可改善AUC。

核心结论

  • TgAb免疫分析间存在显著定性与定量差异,部分试剂用LOQ可改善干扰性TgAb检出。
  • 所有TgAb免疫分析作为疾病替代标志物临床性能欠佳,Tg与TgAb联合仅 modestly 改善。

研究设计与样本

  • 用质谱法测Tg和四对Tg/TgAb免疫分析(Beckman、Roche、Siemens、Thermo)检测576份样本。
  • 用定量下限(LOQ)和厂商参考区间上限(URI)切点进行比较,临床性能用ROC曲线分析评估。

主要发现

  • TgAb免疫分析间定量与定性一致性中等,R²为0.20-0.70,用LOQ时κ为0.41-0.66,用URI时κ为0.47-0.71。
  • 在TgAb干扰样本中,Beckman、Siemens、Thermo用LOQ与URI检出率相似,Roche用URI时检出率明显较低。
  • TgAb阳性病例中,TgAb免疫分析ROC AUC分别为Beckman 0.59、Siemens 0.62、Roche 0.59、Thermo 0.59,与Tg的ROC AUC相似。
  • 联合Tg与TgAb测量较单独Tg或TgAb改善ROC AUC。

关键数值与推荐

  • TgAb免疫分析间定量一致性R²为0.20-0.70。
  • 用LOQ时定性一致性κ为0.41-0.66,用URI时κ为0.47-0.71。
  • TgAb阳性者TgAb免疫分析ROC AUC为0.59(Beckman)、0.62(Siemens)、0.59(Roche)、0.59(Thermo)。

临床怎么用

  • 甲状腺癌随访中应关注TgAb免疫分析间的差异,不宜直接互换不同试剂的结果。
  • 对部分TgAb免疫分析,采用LOQ而非URI作为切点可能提高干扰性TgAb的检出。
  • Tg与TgAb联合检测可能较单独检测提供更好的临床性能,但总体仍欠佳。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While thyroglobulin autoantibodies (TgAb) can result in false low serum thyroglobulin (Tg) immunoassay (IA) measurements, they might also be indicators of disease persistence/recurrence. Hence, accurate TgAb measurement, in addition to Tg quantification, is crucial for thyroid cancer monitoring. We compared the analytical and clinical performance of four commonly used TgAb IAs. METHODS: We measured Tg by mass spectrometry (Tg-MS) and by four pairs of Tg and TgAb IAs (Beckman, Roche, Siemens, Thermo) in 576 samples. Limit of quantitation (LOQ) and manufacturers' upper reference interval cut-off (URI) were used for comparisons. Clinical performance was assessed by receiving operator characteristics (ROC) curve analysis. RESULTS: Quantitative and qualitative agreement between TgAb-IAs was moderate with R2 of 0.20-0.70 and κ from 0.41-0.66 using LOQ and 0.47-0.71 using URI. In samples with TgAb interference, detection rates of TgAb were similar using LOQ and URI for Beckman, Siemens, and Thermo, but much lower for the Roche TgAb-IA when the URI was used. In TgAb positive cases, the ROC areas under the curve (AUC) for the TgAb-IAs were 0.59 (Beckman), 0.62 (Siemens), 0.59 (Roche), and 0.59 (Thermo), similar to ROC AUCs achieved with Tg. Combining Tg and TgAb measurements improved the ROC AUCs compared to Tg or TgAb alone. CONCLUSIONS: TgAb-IAs show significant qualitative and quantitative differences. For 2 of the 4 TgAb-IAs, using the LOQ improves the detection of interfering TgAbs. All assays showed suboptimal clinical performance when used as surrogate markers of disease, with modest improvements when Tg and TgAb were combined.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Katrangi W, Grebe SKG, Algeciras-Schimnich A, et al. Analytical and clinical performance of thyroglobulin autoantibody assays in thyroid cancer follow-up. Clin Chem Lab Med. 2017. PMID: 28672730. doi:10.1515/cclm-2017-0034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。